Psoriasis alters HDL composition and cholesterol efflux capacity

Journal of Lipid Research

Volumn 53, Issue 8, 2012, Pages 1618-1624

  Holzer, Michael ^a   Wolf, Peter ^a   Curcic, Sanja ^a   Birner Gruenberger, Ruth ^a   Weger, Wolfgang ^a   Inzinger, Martin ^a   El Gamal, Dalia ^a   Wadsack, Christian ^a   Heinemann, Akos ^a   Marsche, Gunther ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Cardiovascular disease; High density lipoprotein; Inflammation; Paraoxonase; Phospholipids; Proteome

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID; PROTEINASE;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CHOLESTEROL TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; LIPID COMPOSITION; MACROPHAGE; MALE; MASS SPECTROMETRY; OXIDATION; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEOMICS; PSORIASIS; ULTRACENTRIFUGATION;

ADULT; BIOLOGICAL TRANSPORT; CHOLESTEROL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MACROPHAGES; MALE; PROTEOMICS; PSORIASIS;

EID: 84863805881     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M027367     Document Type: Article

References (38)

1. Flammer, A. J., and F. Ruschitzka. Psoriasis and atherosclerosis: two plaques, one syndrome? Eur. Heart J. Epub ahead of print. November 21, 2011; doi:10.1093/eurheartj/ehr425.
2. Neimann, A. L., D. B. Shin, X. Wang, D. J. Margolis, A. B. Troxel, and J. M. Gelfand. 2006. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 55: 829-835. (Pubitemid 44556851)
3. Kaplan, M. J. 2008. Cardiometabolic risk in psoriasis: differential effects of biologic agents. Vasc. Health Risk Manag. 4: 1229-1235.
4. Gerdes, S., and U. Mrowietz. 2009. Impact of comorbidities on the management of psoriasis. Curr. Probl. Dermatol. 38: 21-36.
5. Mehta, N. N., R. S. Azfar, D. B. Shin, A. L. Neimann, A. B. Troxel, and J. M. Gelfand. 2010. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur. Heart J. 31: 1000-1006.
6. Gelfand, J. M., A. L. Neimann, D. B. Shin, X. Wang, D. J. Margolis, and A. B. Troxel. 2006. Risk of myocardial infarction in patients with psoriasis. JAMA. 296: 1735-1741. (Pubitemid 44547793)
7. Rocha-Pereira, P., A. Santos-Silva, I. Rebelo, A. Figueiredo, A. Quintanilha, and F. Teixeira. 2001. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin. Chim. Acta. 303: 33-39. (Pubitemid 32121803)
8. McGillicuddy, F. C., M. M. de la Llera, C. C. Hinkle, M. R. Joshi, E. H. Chiquoine, J. T. Billheimer, G. H. Rothblat, and M. P. Reilly. 2009. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 119: 1135-1145.
9. Annema, W., N. Nijstad, M. Tolle, J. F. de Boer, R. V. Buijs, P. Heeringa, M. van der Giet, and U. J. Tietge. 2010. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J. Lipid Res. 51: 743-754.
10. Khera, A. V., M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M. F. Burke, K. Jafri, B. C. French, J. A. Phillips, M. L. Mucksavage, R. L. Wilensky, et al. 2011. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364: 127-135.
11. Besler, C., K. Heinrich, L. Rohrer, C. Doerries, M. Riwanto, D. M. Shih, A. Chroni, K. Yonekawa, S. Stein, N. Schaefer, et al. 2011. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J. Clin. Invest. 121: 2693-2708.
12. Van Lenten, B. J., S. Y. Hama, F. C. de Beer, D. M. Stafforini, T. M. McIntyre, S. M. Prescott, B. N. La Du, A. M. Fogelman, and M. Navab. 1995. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96: 2758-2767.
13. Barter, P. J., S. Nicholls, K. A. Rye, G. M. Anantharamaiah, M. Navab, and A. M. Fogelman. 2004. Antiinflammatory properties of HDL. Circ. Res. 95: 764-772. (Pubitemid 39390578)
14. Alwaili, K., D. Bailey, Z. Awan, S. D. Bailey, I. Ruel, A. Hafiane, L. Krimbou, S. Laboissiere, and J. Genest. 2012. The HDL proteomein acute coronary syndromes shifts to an inflammatory profile. Biochim. Biophys. Acta. 1821: 405-515.
15. Holzer, M., R. Birner-Gruenberger, T. Stojakovic, D. El-Gamal, V. Binder, C. Wadsack, A. Heinemann, and G. Marsche. 2011. Uremia alters HDL composition and function. J. Am. Soc. Nephrol. 22: 1631-1641.
16. Davidsson, P., J. Hulthe, B. Fagerberg, and G. Camejo. 2010. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 30: 156-163.
17. Levels, J. H., B. Bleijlevens, F. Rezaee, J. M. Aerts, and J. C. Meijers. 2007. SELDI-TOF mass spectrometry of high-density lipoprotein. Proteome Sci. 5: 15.
18. Davidson, W. S., R. A. Silva, S. Chantepie, W. R. Lagor, M. J. Chapman, and A. Kontush. 2009. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 29: 870-876.
19. Vaisar, T., S. Pennathur, P. S. Green, S. A. Gharib, A. N. Hoofnagle, M. C. Cheung, J. Byun, S. Vuletic, S. Kassim, P. Singh, et al. 2007. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 117: 746-756. (Pubitemid 46348533)
20. Mallbris, L., F. Granath, A. Hamsten, and M. Stahle. 2006. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 54: 614-621.
21. Holzer, M., M. Gauster, T. Pfeifer, C. Wadsack, G. Fauler, P. Stiegler, H. Koefeler, E. Beubler, R. Schuligoi, A. Heinemann, et al. 2011. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid. Redox Signal. 14: 2337-2346.
22. El-Gamal, D., M. Holzer, M. Gauster, R. Schicho, V. Binder, V. Konya, C. Wadsack, R. Schuligoi, A. Heinemann, and G. Marsche. 2012. Cyanate is a novel inducer of endothelial icam-1 expression. Antioxid. Redox Signal. 16: 129-137.
23. Holzer, M., K. Zangger, D. El-Gamal, V. Binder, S. Curcic, V. Konya, R. Schuligoi, A. Heinemann, and G. Marsche. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid. Redox Signal. Epub ahead of print. May 8, 2012; doi:10.1089/ars.2011. 4403.
24. Kelesidis, T., J. S. Currier, D. Huynh, D. Meriwether, C. Charles-Schoeman, S. T. Reddy, A. M. Fogelman, M. Navab, and O. O. Yang. 2011. A biochemical fluorometric method for assessing the oxidative properties of HDL. J. Lipid Res. 52: 2341-2351.
25. Aviram, M., M. Rosenblat, C. L. Bisgaier, R. S. Newton, S. L. Primo-Parmo, and B. N. La Du. 1998. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 101: 1581-1590. (Pubitemid 28198486)
26. Marathe, G. K., G. A. Zimmerman, and T. M. McIntyre. 2003. Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles. J. Biol. Chem. 278: 3937-3947. (Pubitemid 36801125)
27. Watanabe, J., V. Grijalva, S. Hama, K. Barbour, F. G. Berger, M. Navab, A. M. Fogelman, and S. T. Reddy. 2009. Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J. Biol. Chem. 284: 18292-18301.
28. Tölle, M., T. Huang, M. Schuchardt, V. Jankowski, N. Prufer, J. Jankowski, U. J. Tietge, W. Zidek, and M. van der Giet. 2012. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc. Res. 94: 154-162.
29. Weichhart, T., C. Kopecky, M. Kubicek, M. Haidinger, D. Doller, K. Katholnig, C. Suarna, P. Eller, M. Tolle, C. Gerner, et al. 2012. Serum amyloid A in uremic HDL promotes inflammation. J. Am. Soc. Nephrol. 23: 934-947.
30. Fournier, N., J. L. Paul, V. Atger, A. Cogny, T. Soni, M. Llera-Moya, G. Rothblat, and N. Moatti. 1997. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler. Thromb. Vasc. Biol. 17: 2685-2691.
31. Charles-Schoeman, C., Y. Y. Lee, V. Grijalva, S. Amjadi, J. Fitzgerald, V. K. Ranganath, M. Taylor, M. McMahon, H. E. Paulus, and S. T. Reddy. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. Epub ahead of print. January 20, 2012; doi:10.1136/annrheumdis-2011-200493.
32. Watanabe, J., C. Charles-Schoeman, Y. Miao, D. Elashoff, Y. Y. Lee, G. Katselis, T. D. Lee, and S. T. Reddy. 2012. Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis. Arthritis Rheum. 64: 1828-1837.
33. Charles-Schoeman, C., J. Watanabe, Y. Y. Lee, D. E. Furst, S. Amjadi, D. Elashoff, G. Park, M. McMahon, H. E. Paulus, A. M. Fogelman, et al. 2009. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 60: 2870-2879.
34. Srivastava, R., S. Yu, B. W. Parks, L. L. Black, and J. H. Kabarowski. 2011. Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum. 63: 201-211.
35. Davidovici, B. B., N. Sattar, J. C. Prinz, L. Puig, P. Emery, J. N. Barker, P. van de Kerkhof, M. Stahle, F. O. Nestle, G. Girolomoni, et al. 2010. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J. Invest. Dermatol. 130: 1785-1796.
36. Mallet, A. I., and F. M. Cunningham. 1985. Structural identification of platelet activating factor in psoriatic scale. Biochem. Biophys. Res. Commun. 126: 192-198. (Pubitemid 15126608)
37. Izaki, S., T. Yamamoto, Y. Goto, S. Ishimaru, F. Yudate, K. Kitamura, and M. Matsuzaki. 1996. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. Br. J. Dermatol. 134: 1060-1064. (Pubitemid 26183139)
38. Thompson, A., P. Gao, L. Orfei, S. Watson, A. E. Di, S. Kaptoge, C. Ballantyne, C. P. Cannon, M. Criqui, M. Cushman, et al. 2010. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 375: 1536-1544.